BioPharmSignal logoBioPharmSignal

Biotech News

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine (PRME)Prime MedicineEarnings

-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue with the FDA toward BLA filing for PM359 in CGD -- -- Strengthened leadership team with

Related news

PRMEPrime Medicine2026-08-06 12:00 EST

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

PRMEPrime Medicine2025-11-07 12:00 EST

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

View all latest news

Prime Medicine

Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo. PM577 PM577 is an in vivo Prime Editing candidate designed to...

Recent company news

PRMEPrime Medicine2026-08-06 12:00 EST

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

PRMEPrime Medicine2026-07-23 20:05 EST

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

PRMEPrime Medicine2026-07-08 12:00 EST

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

PRMEPrime Medicine2026-06-22 12:00 EST

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

PRMEPrime Medicine2026-06-18 12:00 EST

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Stock data

Close
2.95 USD
Market cap
579.78M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States